Oscar Health shares jumped 3.8% before the market opened, reaching a 52-week peak of $28.16 after Barclays upgraded the insurer from Equalweight to Overweight and boosted its price target to $35 from $30 - the most bullish view the bank has expressed on the stock.
The Barclays move arrives amid growing Wall Street conviction that Oscar’s profitability reset is holding up. InvestingPro’s fair value estimate for the company sits at $29.58, a figure that sits below Barclays’ newly established target but above the recent trading level prior to today’s pre-market rise.
Analysts and investors have been digesting a string of company-specific developments that helped sway sentiment. At the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, CFO Scott Blackley described 2026 as off to a "very strong start," noting that May healthcare utilization tracked better than feared. Blackley also reported that the final 2025 Wakely actuarial report came in $130 million favorable to the company’s first-quarter accruals. He flagged that early market morbidity data was running below expectations and suggested there could be upside to Oscar’s full-year guidance.
These comments reinforced the story told by Oscar’s first-quarter 2026 results. The company reported $679 million in net income and diluted earnings per share of $2.07 - nearly double analyst estimates. Oscar also posted an improved medical loss ratio of 70.5%, down from 75.4% in the prior year period.
Competitive dynamics also factored into investor enthusiasm. The Cigna Group announced plans to exit the ACA market in 2027, and Aetna exited at the start of 2026. Oscar’s CFO explicitly pointed to geographic overlap with carriers that are leaving as an opportunity for growth heading into 2027.
Market context was muted: the broader market provided little lift, with the S&P 500 edging lower and the NASDAQ declining. That divergence underscores that the move in Oscar’s shares was being driven largely by company-specific developments rather than by a broad market rally.
Taken together, Barclays’ upgrade, the CFO’s upbeat conference commentary, and a more favorable competitive backdrop combined to push OSCR to a new 52-week high in pre-market trading. The move extends a year-to-date advance that has already surpassed 80% as investors reprice the company’s earnings prospects.
Context limitations: The analysis above reflects only the developments and figures provided by company announcements, Barclays’ rating action, the CFO’s remarks at the healthcare conference, InvestingPro’s fair-value estimate, and the reported market performance. No additional market data or external commentary has been introduced.